Tempus AI acquires Paige in an $81.25 million deal, adding FDA-cleared cancer detection tools and a dataset of 7 million ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this year. The company now expects full-year revenue to come in at roughly $1.26 ...

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Tempus AI (NASDAQ:TEM) stock sees a 9% pre-market gain as the company raises its 2025 revenue outlook amid strong Q2 performance. Read more here.

Tempus AI (NASDAQ:TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81 ...

After performing well in the first several weeks of 2025, Tempus AI stock hit a high-water mark and closed at $89.44 on Feb. 14, representing a 124% gain over its opening price.

It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can ...